Biliary Tract Neoplasms, Hepatobiliary Neoplasms, Liver Neoplasms
Conditions
Keywords
NGS, Liver Neoplasms, Biliary Tract Neoplasms, Hepatobiliary Neoplasms
Brief summary
The purpose of this study is to explore the precise treatment in hepatobiliary cancer patients and evaluate drug safety, progression free and overall survival. This trial study is based on genetic tests, then therapeutic target drugs are administered according to the genetic test reports. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit from precise treatment which targets particular genetic abnormality. The identifications of these genetic abnormalities may help treat hepatobiliary cancer patients better.
Detailed description
The genetic tests are performed for the eligible subjects in this study, then therapeutic target drugs are administered according to the genetic test reports. While the precise treatments, follow-ups are conducted to evaluate the efficacy and safety of the target drugs for the subjects, until the overall survival. Study Type: Non-Interventional. Masking: Open Label.
Interventions
GENETICPrecise treatment
During screening stage, all patients should accept next-generation sequencing (NGS) test.
Sponsors
3D Medicines
Peking Union Medical College Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Age from 18 to 65, male or female. * Radiologically and pathologically confirmed as hepatobiliary cancers with stage IV. * Palliative care as the preferred. * The result of next-generation sequencing (NGS) test show the patient has gene mutation and also can be treated by the right commercial products that have been approved by the China Food and Drug Administration (CFDA) or the Food and Drug Administration (FDA). * ECOG performance status 0-2. * Life expectancy ≥3 months. * Voluntarily participate in the study and agree to sign informed consent form.
Exclusion criteria
* Hepatobiliary cancer patient with stageI-III, or with any of the following items will not be eligible for screening.Such as, suitable for the treatment of radical resection, radical resection but evaluation unmeasurable. * The result of NGS test show the patient has no gene mutation, or has gene mutation but no medicine. * ECOG performance status ≥ 3. * Female patients who are pregnant or not using a contraceptive method of birth control. * History or presence of serious cardiovascular or cerebrovascular abnormalities. * Abnormalities of the hepatic or renal functions, such as jaundice, ascites, bilirubin ≥ 1.5×ULN, alkaline phosphatase ≥ 3×ULN, persistent protein urine≥ grade 3 (according to National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTC-AE\] v4.0), creatinine ratio \> 3.5g/24 hours, renal failure. * Persistent infection \> grade 2 (according to National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTC-AE\] v4.0). * Patient has underwent a major operation 4 weeks prior to screening or has not yet recovered from the operation. * Patient with epilepsy, known or untreated brain metastases. * The presence of wounds, ulcers or fractures that can not be healed, or with a past history of transplantation. * The presence of bleeding events ≥grade 3 (according to National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTC-AE\] v4.0) , present evidence or past history of coagulation dysfunction disorders. * Known human immunodeficiency virus (HIV) infection history. * Patient with drug abuse or unstable compliance. * The presence of unresolved toxicity caused by any previous treatment/operation \> grade 1 (according to National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTC-AE\] v4.0), except alopecia, anemia or hypothyroidism). * Investigator consider that the patient should not be enrolled in this study by careful assessment. * The subjects participate in any other clinical trial in the meantime.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rates (ORR) | 6 weeks | Defined as the percentage of patients whose tumors have a complete or partial response to treatment (RECIST v1.1) . |
| Progression-free survival (PFS) | 8 months | Progression-free survival (PFS) is the time that passes from the day in which the patient is enrolled in the trial until the date on which disease progresses or the date of death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | Through study completion, an average of 1 year. | Overall survival (OS) is the duration from the day in which the patient is enrolled in the trial until the date of death from any cause. |
| Duration of Response (DOR) | 6 months | Duration of Response (DOR) is the duration from the first assessment of the tumor was CR or PR to the time that the first assessment for PD (Progressive Disease) or date of death from any cause. |
| Disease control rate (DCR) | 6 weeks | Defined as the percentage of patients whose tumors have a complete or partial response，or stable disease to treatment (RECIST v1.1). |
| Adverse Drug Reaction (ADR)/Adverse Event (AE) | Through study completion, an average of 2 years. | Patients with treatment-related adverse events as assessed by CTC-AE v4.0. |
Countries
China
Contacts
Primary ContactYuan Xie, Doctor
Backup ContactXiao-Bo Yang, Doctor
Outcome results
None listed